Study into the effect of atomoxetine on freezing of gait in Parkinson's Grant from Michael J. Fox Foundation for international study led by Radboudumc

A multidisciplinary research team led by Jorik Nonnekes at Radboud university medical center is leading an international study looking into the effects of atomoxetine as a medication against freezing of gait in people with Parkinson's disease. The amount awarded is 1.4 million euros.

Freezing of gait is a common and challenging motor symptom in people with Parkinson's disease, in which the feet literally 'stick' to the ground, making the next step very difficult. This phenomenon, which often occurs when starting to walk, turning, or in stressful situations, can seriously limit the mobility of patients. Current medication does not provide sufficient relief. That is why there is an urgent need for new treatment options.

In an international study, led by a multidisciplinary team of researchers from Radboudumc (Nijmegen), University of Waterloo (Canada), and Macquarie University (Australia), the effect of the drug atomoxetine on freezing of gait in Parkinson's is being investigated. Atomoxetine is a drug currently used to treat ADHD, treating the system in the brain that ensures alertness and arousal. When this system is overactive, it can contribute to freezing of gait, especially in people who are sensitive to stress or anxiety.

Jorik Nonnekes, rehabilitation physician and research leader: 'We see great promise in this drug for people with Parkinson's who suffer from freezing of gait. Atomoxetine may improve communication between brain areas, which reduces freezing. The aim is to reduce freezing of gait, and thus also improve the well-being of patients.'

This international collaboration paves the way for a promising, patient-tailored treatment option for one of the most limiting symptoms of Parkinson's. Sixty Parkinson's patients will participate in the study, in which they will receive atomoxetine or placebo in different sessions. The study focuses not only on the impact on freezing of gait, but also on the underlying brain activity, measured through brain scans.

This research is funded by Michael J. Fox Foundation for Parkinson’s Research. The amount awarded is 1.4 million euros.

In this picture: rehabilitation physician and research leader Jorik Nonnekes.